Key result
Vaccine-associated myocarditis is linked to ~51% higher healthcare utilization over 18 months versus unexposed vaccinees.
Why the study?
The study evaluated all-cause healthcare utilization among individuals with vaccine-associated myocarditis compared to vaccinees without postvaccination myocarditis.
Does vaccine-associated myocarditis increase healthcare utilization compared to vaccination without myocarditis in individuals aged 12 and older?
Cohort
Does vaccine-associated myocarditis increase healthcare utilization compared to vaccination without myocarditis in individuals aged 12 and older?
Vaccine-associated myocarditis leads to a temporary increase in healthcare utilization for the first 6 months, followed by a return to baseline, indicating a positive long-term prognosis.
Answers are grounded in this paper and cite their sources.
Associated with transient healthcare utilization increase; leaves open optimal monitoring duration after vaccine-associated myocarditis.
OBJECTIVES: We evaluated all-cause healthcare utilization among those with vaccine-associated myocarditis, compared to vaccinees without postvaccination myocarditis. METHODS: We conducted a retrospective cohort study in individuals aged 12 and older who received COVID-19 mRNA vaccination in British Columbia. Exposure was defined as an ED visit or hospitalization for myocarditis within 21 days postvaccination. The primary outcome was healthcare utilization. Ratios of rate ratios (RRRs) for exposure-associated healthcare utilization were calculated using a difference-in-differences (DiD) analysis. RESULTS: In the postindex period, the exposed and unexposed groups showed substantial utilization rate difference (RD = 15.30 [95% CI, 14.47-16.13). A 51% overall increase in healthcare utilization was observed over 18 months among exposed individuals (RRR, 1.51 [95%CI, 1.08-2.11]). In the initial six months, healthcare utilization surpassed the 18-month estimate, exhibiting a 125% increase (RRR, 2.25 [95%CI, 1.43-3.52]), while the last 12 months showed no statistically significant change (RRR, 1.03 [95%CI, 0.72-1.47]). An additional 9.1 (95%CI, 8.53-9.71) visits per person were attributed to vaccine-associated myocarditis over 18 months (total excess = 938.26 healthcare visits). CONCLUSION: The initial surge in healthcare visits postexposure, mainly outpatient follow-ups, followed by a return to baseline rates, indicates a positive prognosis and supports the vaccine's safety profile.
No takes yet. Share an insight, caveat, or question.
Naveed et al. (2024) conducted a cohort in COVID-19 mRNA vaccine-associated myocarditis. Vaccine-associated myocarditis vs. Vaccinees without postvaccination myocarditis was evaluated on Healthcare utilization (RRR 1.51, 95% CI 1.08-2.11). Vaccine-associated myocarditis was associated with a 51% increase in healthcare utilization over 18 months compared to unexposed vaccinees.
Synapse has enriched 10 related papers. Consider them for comparative context: